Gilead's shares rose 1.3% to $62.30, while Merck was up nearly 2% at $76.08. It was also shown to stand up against variants first reported in the U.K., South Africa, Brazil, California, New York and India. Potential side effects include anaphylaxis and infusion-related reactions such as rash and diarrhea. Reporting By Mrinalika Roy in Bengaluru; Editing by Shounak DasguptaOur Standards: The Thomson Reuters Trust Principles. 1.7 million new HIV infections were reported globally in 2019 and 38 million people were living with HIV, according to the World Health Organization.
Gilead's shares rose 17.9% to $80.00.
( z0 rise :ARG1 ( z1 share :poss ( z2 company :name ( z3 name :op "Gilead" ) ) ) :ARG2 ( z4 percentage-entity :value 17.9 ) :ARG4 ( z5 monetary-quantity :quant 80.00 :unit ( z6 dollar ) ) )
(z0 / rise-01
    :ARG1 (z1 / share
              :poss (z2 / company
                        :name (z3 / name
                                  :op1 "Gilead")))
    :ARG2 (z4 / percentage-entity
              :value 17.9)
    :ARG4 (z5 / monetary-quantity
              :quant 80.00
              :unit (z6 / dollar)))
Gilead 's shares rose 17.9 % to $ 80.00 .
z2 :name z3
z3 :op1 2
z1 :poss z2
z0 :ARG1 z1
z4 :value 0
z0 :ARG2 z4
z0 :ARG4 z5
z5 :unit z6
z5 :quant 1